# First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC

> **NCT01284205** · PHASE3 · WITHDRAWN · sponsor: **Bioniche Life Sciences Inc.**

## Conditions studied

- Bladder Cancer

## Interventions

- **BIOLOGICAL:** Mycobacterial Cell-Wall DNA Complex
- **BIOLOGICAL:** Bacillus Calmette-Guerin

## Key facts

- **NCT ID:** NCT01284205
- **Lead sponsor:** Bioniche Life Sciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-01
- **Primary completion:** 2014-02
- **Final completion:** 2017-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This indication is not being pursued at this point in time.
- **Last updated:** 2014-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01284205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01284205, "First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01284205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*